Divi's Laboratories Limited — Q1FY27 earnings call summary

Filed 06 August 2026 · Official transcript

Ongoing capex projects nearing completion; validation batches progressing
Gross margin approx. 68% in Q1; full-year margin expected near last year's level
Q1 FY27 consolidated total income ₹3,144 Cr (+24% y-y); PAT ₹902 Cr (+65% y-y)
Regulatory approvals key for commercial ramp-up of new projects
Management targets sustained double-digit revenue growth for FY27
Peptide capacity expanding with new 3,000-liter SPPS installations
Custom Synthesis contributed 60% of revenue; Generics 40%
Supply chain challenges persist; 3-month inventory buffer maintained